Aiming to address the real impact of HDAC on the chemotherapeutic induction of MCL, French researchers conducted a phase II study with the hybrid regimen R-CHOP/R-DHAP followed by ASCT in 60 patients newly diagnosed with MCL. Here, HDAC9 is linked to mantle cell lymphoma.